Our results provide an additional rationale for checkpoint co-blockades in high-risk soft tissue sarcomas, and support current clinical trials on combinations of anti-TIM-3 and anti-PD-1 antibodies in solid tumors. This evidence concerns the gene HAVCR2 and soft tissue sarcoma.